A comparative study of functional assays for tissue factor pathway inhibitor using normal plasma and clinical samples

被引:10
作者
Adams, MJ [1 ]
Oostryck, R [1 ]
机构
[1] Curtin Univ Technol, Sch Biomed Sci, Perth, WA 6845, Australia
关键词
tissue factor pathway inhibitor; functional assay; thrombosis;
D O I
10.1097/00001721-200006000-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tissue factor pathway inhibitor (TFPI) is a Kunitz-type inhibitor that regulates the initiation of tissue factor-mediated coagulation. Recent reports in the literature have described variable results using different methodologies for TFPI measurement. In this study, we used one clotting and two amidolytic methodologies to assess TFPI functional levels. The study groups included normal healthy donors as well as patients with acute hepatitis, diabetes, coronary artery bypass graft operations, deep vein thrombosis, and prior to and during heparin therapy. The aims were to compare the results obtained in normal plasma using different assay systems, to compare TFPI levels in a range of clinical samples, including those previously not determined using a clotting methodology, and to report TFPI levels in patient groups previously not investigated. The results clearly demonstrate poor correlation between functional TFPI values using the different methodologies, highlighting the requirement for standardization. Blood Coagul Fibrinolysis 11:327-333 (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:327 / 333
页数:7
相关论文
共 24 条
[11]   TISSUE FACTOR PATHWAY INHIBITOR WITH HIGH ANTICOAGULANT ACTIVITY IS INCREASED IN POSTHEPARIN PLASMA AND IN PLASMA FROM CANCER-PATIENTS [J].
LINDAHL, AK ;
JACOBSEN, PB ;
SANDSET, PM ;
ABILDGAARD, U .
BLOOD COAGULATION & FIBRINOLYSIS, 1991, 2 (06) :713-721
[12]   THE PRESENT STATUS OF TISSUE FACTOR PATHWAY INHIBITOR [J].
LINDAHL, AK ;
SANDSET, PM ;
ABILDGAARD, U .
BLOOD COAGULATION & FIBRINOLYSIS, 1992, 3 (04) :439-449
[13]   EXTRINSIC PATHWAY INHIBITOR (EPI) RELEASED TO THE BLOOD BY HEPARIN IS A MORE POWERFUL COAGULATION INHIBITOR THAN IS RECOMBINANT EPI [J].
LINDAHL, AK ;
ABILDGAARD, U ;
LARSEN, ML ;
STAALESEN, R ;
HAMMER, AKG ;
SANDSET, PM ;
NORDFANG, O ;
BECK, TC .
THROMBOSIS RESEARCH, 1991, 62 (06) :607-614
[14]   RELEASE OF EXTRINSIC PATHWAY INHIBITOR AFTER HEPARIN INJECTION - INCREASED RESPONSE IN CANCER-PATIENTS [J].
LINDAHL, AK ;
ABILDGAARD, U ;
STOKKE, G .
THROMBOSIS RESEARCH, 1990, 59 (03) :651-656
[15]  
OSTERGAARD P, 1993, HAEMOSTASIS, V23, P107
[16]  
RAPAPORT SI, 1989, BLOOD, V73, P359
[17]   INITIATION AND REGULATION OF TISSUE FACTOR-DEPENDENT BLOOD-COAGULATION [J].
RAPAPORT, SI ;
RAO, LVM .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (10) :1111-1121
[18]   HEPARIN INDUCES RELEASE OF EXTRINSIC COAGULATION PATHWAY INHIBITOR (EPI) [J].
SANDSET, PM ;
ABILDGAARD, U ;
LARSEN, ML .
THROMBOSIS RESEARCH, 1988, 50 (06) :803-813
[19]   CHROMOGENIC SUBSTRATE ASSAY OF EXTRINSIC PATHWAY INHIBITOR (EPI) - LEVELS IN THE NORMAL POPULATION AND RELATION TO CHOLESTEROL [J].
SANDSET, PM ;
LARSEN, ML ;
ABILDGAARD, U ;
LINDAHL, AK ;
ODEGAARD, OR .
BLOOD COAGULATION & FIBRINOLYSIS, 1991, 2 (03) :425-433
[20]  
SANDSET PM, 1989, THROMB HAEMOSTASIS, V62, P856